Adenosine A2A-receptor antagonists: Beyond dopaminergic therapies for Parkinson's disease

Drug Discovery Today: Therapeutic Strategies

Volumn 1, Issue 1, 2004, Pages 51-57

  Kase, Hiroshi ^a   Mori, Akihisa ^b   Jenner, Peter ^c  

^a Fuence Co Ltd   (Japan)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 (3,4 DIMETHOXYSTYRYL) 7 METHYL 1,3 DIPROPYLXANTHINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; AMANTADINE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; ISTRADEFYLLINE; LEVODOPA; MUSCARINIC M1 RECEPTOR; NICOTINIC RECEPTOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR;

ARTICLE; BRAIN NERVE CELL; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DYSKINESIA; HUMAN; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPROTECTION; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATIENT CARE; PSYCHOSIS; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VOMITING;

EID: 13444249899     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2004.08.016     Document Type: Review

References (40)

1. H. Kase Adenosine receptors and Parkinson's disease Biosci. Biotechnol. Biochem. 65 2001 1447-1457
2. 2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD Neurology 61 Suppl. 6 2003 S32-S38
3. 2A antagonists Neurology 61 Suppl. 6 2003 S44-S48
4. 2A receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease Neuroscience 127 2004 223-231
5. S. Ferre et al. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia Trends Neurosci. 20 1997 482-487
6. B.B. Fredholm P. Svennigsson Adenosine-dopamine interactions. Development of a concept and some comments on therapeutic possibilities Neurology 61 Suppl. 6 2003 S5-S9
7. M. Morelli et al. Dopamine-adenosine interactions In Handbook of Experimental Pharmacology, Vol. 154/II. Dopamine in the CNS II (G. Di Chiara ed) 2002 Springer-Verlag 135-150
8. L. Agnati et al. Molecular mechanisms and therapeutic implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striato-pallidal GABA neurons Pharmacol. Rev. 55 2003 509-550
9. 2A receptor antagonist J. Neurosci. 20 2000 5848-5852
10. 2 receptor knockout mice Proc. Natl. Acad. Sci. 98 2001 1970-1975
11. 2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease Exp. Neurol. 184 2003 285-294
12. 2A receptor antagonists Il Farmaco 56 2001 87-90
13. C.W. Olanow et al. An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines Neurology 56 Suppl. 5 2001 S1-S88
14. E. Bezard et al. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies Nat. Rev. Neurosci. 2 2001 577-588
15. 2A receptor antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys Ann. Neurol. 43 1998 507-513
16. 2A receptor selective antagonist KW-6002: Research and development toward a novel nondopaminergic therapy for Parkinson's disease Neurology 61 Suppl. 6 2003 S97-S100
17. 2A receptor antagonist KW-6002 and its effect on gene expression in the rat brain Brain Res. 953 2002 119-125
18. 2A receptor and striatal cellular functions. Regulation of gene expression, currents, and synaptic transmission Neurology 61 Suppl. 6 2003 S24-S29
19. 2A receptors Prog. Neurobiol. 59 1999 355-396
20. 2A receptor antagonist in MPTP-treated monkeys Neurology 52 1999 1673-1677
21. 2A antagonist: Potential preventive and palliative treatment for Parkinson's disease Exp. Neurol. 184 2003 20-23
22. F. Blandini Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: Potential target for a new therapeutic approach Exp. Neurol. 184 2003 556-560
23. 2A receptor antagonist istradefylline in advanced PD Neurology 61 2003 297-303
24. 2A receptor antagonist treatment of Parkinson's disease Neurology 61 2003 293-296
25. Kase, H. et al. (2003) Method of treating patients suffering from movement disorders. WO03/063876 (Kyowa Hakko)
26. 2A receptor antagonist with anticataleptic activity Eur. J. Pharmcol. 256 1994 263-268
27. 1 agonists in dopamine-denervated rats Eur. J. Neurosci. 8 1996 1176-1181
28. 2A receptors modulate haloperidol-induce catalepsy in rats Eur. J. Pharmcol. 328 1997 135-141
29. 2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP Psychopharmacology 147 1999 90-95
30. 2A receptor antagonists in relevant rodent models Drug Dev. Res. 50 2000 70-87
31. 2A receptor regulation in the rat dopamine-denervated striatum Eur. J. Neurosci. 12 2000 4033-4037
32. 2 dopamine agonists increase antiparkinsonia activity but not dyskinesia in MPTP-treated monkeys Exp. Neurol. 162 2000 321-327
33. 2A receptor modulation Neurology 61 Suppl. 6 2003 S88-S93
34. 2A receptors and depression Neurology 61 Suppl. 6 2003 S82-S87
35. 2A receptor antagonism J. Biol. Chem. 277 2002 36040-36044
36. 2A receptor blockade in experimental models of Parkinson's disease J. Neurochem. 80 2002 262-270
37. 2A adenosine receptor inactivation in an model of Parkinson's disease J. Neurosci. 21 2001 RC143
38. 2A receptor antagonists in animal models of Parkinson's disease Neurology 61 Suppl. 6 2003 S55-S61
39. 2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: Neurodegenerative disease of the striatum J. Neurosci. 22 2002 1967-1975
40. W. Meissner et al. Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials Trends Pharmacol. Sci. 25 2004 249-253